Alpheus™ Medical, Inc, perusahaan swasta sing ngembangake platform terapi sonodinamik (SDT) novel sing nargetake kanker awak padhet, dina iki ngumumake pembentukan Dewan Penasehat Ilmiah (SAB) kanthi janjian para ahli terkemuka ing donya ing bidang neuro- onkologi, bedah saraf, kimia, lan biologi molekuler. Anggota pendiri SAB bakal kalebu Dr. Roger Stupp (Sekolah Kedokteran Universitas Northwestern Feinberg), Dr. David Reardon (Sekolah Kedokteran Harvard lan Institut Kanker Dana-Farber), Dr. Walter Stummer (Rumah Sakit Universitas Münster, Jerman), lan Dr. Mathias Senge (Trinity College Dublin, Irlandia).
"We are bangga kanggo mbewarakke pimpinan utomo donya ing glioblastoma minangka bagéan saka dewan penasehat ilmiah kita," komentar Vijay Agarwal, MD, CEO saka Alpheus Medical. "Kanthi klompok sing misuwur iki, kita siap nerusake kemajuan ing perang nglawan kanker otak sing wis ngalami akeh kegagalan lan inovasi terapi minimal sajrone pirang-pirang dekade. Upaya klinis lan tuntunan saka SAB utama iki bebarengan karo babak pendanaan Seri A $ 16M sing anyar bakal dadi instrumental nalika kita miwiti uji coba FIH lan njelajah bukti studi konsep kanggo kanker tumor padhet liyane.
Perawatan SDT sing diselidiki Alpheus Medical minangka kombinasi piranti obat sing inovatif lan non-invasif sing ngarahake sel kanker ing saindhenging wilahan bumi kanthi nggunakake ultrasonik lapangan gedhe kanthi intensitas rendah. Pangobatan kasebut ditindakake ing setelan rawat omah, bisa diulang maneh, lan ora mbutuhake pencitraan, kayata MRI.
"Aku bungah kanggo mimpin tim dokter lan peneliti sing luar biasa iki nalika kita miwiti enrollment ing uji coba pisanan ing manungsa sajrone sasi sing bakal teka," ujare Roger Stupp, MD, Ketua Alpheus Medical SAB, Co-Direktur Malnati Institut Tumor Otak saka Pusat Kanker Komprehensif Lurie, lan Kepala Neuro-Oncology ing Sekolah Kedokteran Feinberg Universitas Northwestern. "Kanthi selektif nargetake lan mateni sel kanker ing saindenging jagad kanthi SDT, pendekatan Alpheus pancen njanjeni lan duweni potensi kanggo ngganti cara ngobati pasien kanthi glioblastoma berulang."
APA sing kudu dijupuk saka ARTIKEL INI:
- The clinical efforts and guidance of this premier SAB in conjunction with our recent $16M Series A financing round will be instrumental as we embark on our FIH trial and explore proof of concept studies for other solid tumor cancers.
- Alpheus™ Medical, Inc, a privately held company developing a novel sonodynamic therapy (SDT) platform targeting solid body cancers, today announced the formation of their Scientific Advisory Board (SAB) with the appointment of the world’s leading experts in the fields of neuro-oncology, neurosurgery, chemistry, and molecular biology.
- Stated Roger Stupp, MD, Chairman of the Alpheus Medical SAB, Co-Director of the Malnati Brain Tumor Institute of the Lurie Comprehensive Cancer Center, and Chief of Neuro-Oncology at Northwestern University’s Feinberg School of Medicine.
